Showing 1041-1050 of 1116 results for "".
- Study: Zebrafish Model Helps Explain Eye Developmenthttps://modernod.com/news/study-zebrafish-model-helps-explain-eye-development/2481352/Scientists at the National Eye Institute (NEI) have developed a zebrafish model of NEDBEH—a rare genetic disorder that can cause coloboma, where parts of the eye are missing due to developmental defects. The model provides a new tool for understanding the eye's embryonic developmen
- Market Scope: Lens-Based Procedures Will Push Retail Refractive Surgery Market to $12 Billionhttps://modernod.com/news/market-scope-lens-based-procedures-will-push-retail-refractive-surgery-market-to-12-billion/2481338/Market Scope forecasts that the global refractive surgery industry will generate $12 billion in total retail revenue in 2027—up from $8.9 billion in 2022—for a compound growth rate of 6.2 percent. The health care research company expects revenue at the manufacturer level to
- Verana Health Study of Patients with Dry AMD Published in International Ophthalmologyhttps://modernod.com/news/verana-health-study-of-patients-with-dry-amd-published-in-international-ophthalmology/2481301/Verana Health—a digital health company elevating quality in real-world data—announced that Ophthalmology and Therapy, an international, peer-reviewed medical journal, has
- Ocugen Announces OCU400 Receives Orphan Drug Designations for Retinitis Pigmentosa and Leber Congenital Amaurosishttps://modernod.com/news/ocugen-announces-ocu400-receives-orphan-drug-designations-for-retinitis-pigmentosa-and-leber-congenital-amaurosis/2481300/Ocugen announced that the FDA granted orphan drug designations to OCU400—human nuclear hormone receptor subfamily 2 group E member 3 (hNR2E3)—for the treatment of retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA). “Receiving orphan drug designation is
- NovaSight Announces Commercial Release of CureSight in the US; Names a New VP of Sales & Marketinghttps://modernod.com/news/novasight-introduces-curesight-to-the-us-and-names-a-new-vp-of-sales-marketing/2481295/NovaSight has announced that its CureSight digital therapy for amblyopia will be released to the US market beginning this month. CureSight received FDA 510(K) clearance based on a pivotal study that found the device to be noninferior to eye patching—t
- Alcon Completes Acquisition of Aerie Pharmaceuticalshttps://modernod.com/news/alcon-completes-acquisition-of-aerie-pharmaceuticals/2481258/Alcon announced that it has completed its acquisition of Aerie Pharmaceuticals. In August, Alcon announced its was acquiring Aerie for about $770 million, or $15.25 per share—a premium of 37% to Aerie’s closing price prior to the deal. The deal bolsters Alcon's
- Nanodropper Launches 2022 Give the Gift of Vision Campaign to Support Global Access to Eye Carehttps://modernod.com/news/nanodropper-launches-2022-give-the-gift-of-vision-campaign-to-support-global-access-to-eye-care/2481193/Nanodropper launched its "2022 Give the Gift of Vision" program, an effort to donate 1,000 Nanodropper adaptors to at-need patients in the United States and its global nonprofit partners—designed to deliver better access to vision-saving care in low resource settings in
- BVI Announces Certification for its IOL Portfolio Under the European Medical Device Regulationhttps://modernod.com/news/bvi-announces-certification-for-its-iol-portfolio-under-the-european-medical-device-regulation/2481094/BVI announced certification for its IOL portfolio under the European Medical Device Regulation (MDR, (EU) 2017/745) from its Notified Body, the British Standards Institution (BSI)¹. The new regulatory criteria came into effect in May 2021, replacing the prior Medica
- New MaximEyes.com Software Designed to Simplify EHR Navigation and Patient Flowhttps://modernod.com/news/new-maximeyescom-software-designed-to-simplify-ehr-navigation-and-patient-flow/2481076/First Insight has introduced MaximEyes.com, which is desinged go allow eye care processionals to access data—anywhere, anytime, from any device—in a web browser or via a local server.
- Bausch + Lomb Named Exclusive Global Distributor of Alfa Instruments Intraocular Dyeshttps://modernod.com/news/bausch-lomb-named-exclusive-global-distributor-of-alfa-instruments-intraocular-dyes/2481060/Bausch + Lomb and Alfa Instruments announced that the companies have entered into an exclusive distribution agreement under which Bausch + Lomb will distribute and commercialize Alfa Instruments' line of surgical intraocular dyes—Vitreocare—globally with the exception of Italy, wh